EDGAR Online

REGENERON PHARMACEUTICALS INC

Reported by

SCHLEIFER LEONARD S

FORM 4

(Statement of Changes in Beneficial Ownership)

Filed 05/02/12 for the Period Ending 05/01/12

Address	777 OLD SAW MILL RIVER RD TARRYTOWN, NY 10591-6707
Telephone	9143477000
CIK	0000872589
Symbol	REGN
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	12/31

Powered By EDGAR Online
http://www.edgar-online.com
© Copyright 2012, EDGAR Online, Inc. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use.

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *	2. Issuer Name **and** Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
SCHLEIFER LEONARD S	**REGENERON PHARMACEUTICALS INC [REGN]**	__ **X** __ Director _____ 10% Owner __ **X** __ Officer (give title below) _____ Other (specify below) **President & CEO**
(Last) (First) (Middle) **777 OLD SAW MILL RIVER ROAD**	3. Date of Earliest Transaction (MM/DD/YYYY) **5/1/2012**	
(Street) **TARRYTOWN, NY 10591** (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _ **X** _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock								**84773**	**I**	**by GRAT**
Common Stock								**5560**	**I**	**by 401(k) Plan**
Common Stock	**5/1/2012**		**S** (1)		**2300**	**D**	**$133.86** (2)	**384028**	**D**	
Common Stock	**5/1/2012**		**S** (1)		**58494**	**D**	**$134.55** (3)	**325534**	**D**	
Common Stock	**5/1/2012**		**S** (1)		**39106**	**D**	**$135.29** (4)	**286428**	**D**	
Common Stock	**5/1/2012**		**S** (1)		**100**	**D**	**$136.57**	**286328**	**D**	

Table II - Derivative Securities Beneficially Owned (*e.g.* , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Class A Stock	**$0**							(5)	(5)	**Common Stock** (6)	**1710790**		**1710790**	**D**	
Class A Stock	**$0**							(5)	(5)	**Common Stock** (6)	**22275**		**22275**	**I**	**by Trust for Son**

Explanation of Responses:

(1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

(2) Represents volume-weighted average price of sales of 2,300 shares of Company stock on May 1, 2012 at prices ranging from $133.83 to $133.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2012 at each separate price.

(3) Represents volume-weighted average price of sales of 58,494 shares of Company stock on May 1, 2012 at prices ranging from $134.01 to $134.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2012 at each separate price.

(4) Represents volume-weighted average price of sales of 39,106 shares of Company stock on May 1, 2012 at prices ranging from $135.00 to $135.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2012 at each separate price.

(5) Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.

(6) Class A Stock of Regeneron Pharmaceuticals, Inc. ("Regeneron") converts to Common Stock of Regeneron on a one-to-one basis upon certain events.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
SCHLEIFER LEONARD S **777 OLD SAW MILL RIVER ROAD** **TARRYTOWN, NY 10591**	**X**		**President & CEO**	

Signatures

/s/Leonard S. Schleifer** **5/2/2012**

** Signature of Reporting Person — Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

***** If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

****** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.